Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL27932051 | 0.71 | — | — | |
| SCHEMBL1577820 | 0.71 | — | — | |
| SCHEMBL68353 | 0.67 | — | — | |
| SCHEMBL11028940 | 0.67 | MAOA (0.40) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL12360481 | 0.67 | BRD4 (0.39) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL1955321 | 0.67 | CHRNA7 (0.50) | — | |
| SCHEMBL1958525 | 0.67 | — | — | |
| SCHEMBL4189631 | 0.65 | — | — | |
| SCHEMBL2306907 | 0.65 | — | — | |
| SCHEMBL378435 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-05 | — | — | US | disclosed |
| EP-3004096-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195919-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-11 | — | — | WO | disclosed |
| US-8703165-B2 | Spiro fused 1-amino-piperdine pyrrolidine dione derivatives with pesticidal activity | SYNGENTA CROP PROTECTION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2507240-B1 | SPIRO FUSED 1-AMINO-PIPERIDINE PYRROLIDINE DIONE DERIVATIVES WITH PESTICIDAL ACTIVITY | SYNGENTA PARTICIPATIONS AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-8541343-B2 | Chemical compounds and their use as pesticides | SYNGENTA CROP PROTECTION, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2507214-A1 | CHEMICAL COMPOUNDS AND THEIR USE AS PESTICIDES | Syngenta Participations AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507240-A1 | SPIRO FUSED 1 -AMINO - PIPERIDINE PYRROLIDINE DIONE DERIVATIVES WITH PESTICIDAL ACTIVITY | Syngenta Participations AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245026-A1 | SPIRO FUSED 1-AMINO - PIPERDINE PYRROLIDINE DIONE DERIVATIVES WITH PESTICIDAL ACTIVITY | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120238452-A1 | CHEMICAL COMPOUNDS AND THEIR USE AS PESTICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011067135-A1 | SPIRO FUSED 1 -AMINO - PIPERIDINE PYRROLIDINE DIONE DERIVATIVES WITH PESTICIDAL ACTIVITY | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067203-A1 | CHEMICAL COMPOUNDS AND THEIR USE AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067240-A1 | SPIRO FUSED 1 -AMINO - PIPERIDINE PYRROLIDINE DIONE DERIVATIVES WITH PESTICIDAL ACTIVITY | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245026-A1 | SPIRO FUSED 1-AMINO - PIPERDINE PYRROLIDINE DIONE DERIVATIVES WITH PESTICIDAL ACTIVITY | DDT, CAT, AQP1 | TRIM24 3938/4885TRIM33 4262/4885ALDH1A1 79/4885 |
| US-20120238452-A1 | CHEMICAL COMPOUNDS AND THEIR USE AS PESTICIDES | DDT, ACHE, CYP1A1 | TRIM24 4205/4885TRIM33 3465/4885ALDH1A1 140/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TRIM24 4038/4885TRIM33 3866/4885ALDH1A1 4542/4885 |
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | TRIM24 1482/4885TRIM33 2521/4885ALDH1A1 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.